Prelude Therapeutics (PRLD) Current Deferred Revenue (2024 - 2026)

Prelude Therapeutics (PRLD) reported Current Deferred Revenue of $31.0 million for Q1 2026, down 8.25% sequentially from $33.7 million in Q4 2025.

Prelude Therapeutics (PRLD) Current Deferred Revenue (2024 - 2026) Analysis & Trends

Prelude Therapeutics (PRLD) has 3 years of Current Deferred Revenue data on file, last reported at $31.0 million in Q1 2026.

For the quarter ending Q1 2026, Current Deferred Revenue changed N/A year-over-year to $31.0 million; the trailing twelve-month figure through Mar 2026 stood at $31.0 million (changed N/A YoY), and the FY2025 full-year result was $33.7 million, changed N/A from the prior year.
Current Deferred Revenue declined to $31.0 million in Q1 2026, from $33.7 million in the prior quarter.
In the past five years, Current Deferred Revenue ranged from a high of $33.7 million in Q4 2025 to a low of $3.0 million in Q2 2024.
A 3-year average of $22.6 million and a median of $31.0 million in 2026 frame the typical range for Current Deferred Revenue.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Prelude Therapeutics	324.30 Mn	179.71 Mn	-

Download Data